Baird Says Time is Right to Own NewLink Genetics (NLNK)

October 31, 2012 1:49 PM EDT Send to a Friend
Get Alerts NLNK Hot Sheet
Price: $45.16 +4.83%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 45 | New: 12
Trade NLNK Now!
Join SI Premium – FREE
Baird reiterated an Outperform rating on NewLink Genetics (NASDAQ: NLNK) and raised its price target to $20.00 (from $17.00).

"Though the quarterly print was uneventful, we continue to like NLNK for its significant pipeline potential, with first HyperAcute Pancreas Phase III interim look in early-2013 – an event that we think brings real un-modeled upside potential as our base case assumes a 2015 approval," said analyst Christopher J. Raymond.

He thinks the stock recent 15 percent pullback offers a compelling entry point in front of the pivotal HyperAcute data next year.

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $13.81 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment